Current Report Filing (8-k)
October 07 2016 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 7, 2016
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36500
|
|
94-3103561
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address
of principal executive offices)
(510) 293-8800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On October 7, 2016, CymaBay Therapeutics, Inc. (the
“Company”) posted the slide presentation (the “Corporate Presentation”), attached here as Exhibit 99.1 to this report, to its corporate website which includes recent updates to the Company’s clinical development programs.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
|
|
99.1
|
|
Corporate Presentation
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
CymaBay Therapeutics, Inc.
|
|
|
|
|
By:
|
|
/s/ Sujal Shah
|
|
Name:
|
|
Sujal Shah
|
|
Title:
|
|
Chief Financial Officer
|
Dated: October 7, 2016
EXHIBIT INDEX
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
|
|
99.1.
|
|
Corporate Presentation
|
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Apr 2023 to Apr 2024
